Gilead/Bristol Hep C Combo Gets High Marks At EASL, But Its Future Is In Doubt
All eyes are on Gilead Sciences following the news it may not continue development of GS-7977 alongside Bristol-Myers Squibb’s daclatasvir, though the all-oral pairing produced impressive data in Phase II.
You may also be interested in...
At the AASLD conference, Bristol talked up its filing of a two-drug oral combination to treat hepatitis C in Japan, which would be the first oral combo regimen to reach market for the virus. But with plans to end discovery research in HCV, will the pharma focus its virology efforts more on hepatitis B and HIV?
It was all good news for Gilead at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13, where the company produced evidence it can develop an effective and entirely unpartnered all-oral combination therapy against hepatitis C – but the combination still has to hold up in Phase III trials.
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.